Known targets — ChEMBL curated mechanism
AURKAAURKBAURKCBLKFGRFLT1FLT4FRKFYNHCKKDRLCKLYNPDGFRAPDGFRBSRCSRMSYES1
The experimentally established mechanism targets of Ilorasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 17/20 | 1.00 |
| ▸ | AURKB known ✓ | Q96GD4 | 12/20 | 1.00 |
| ▸ | BLK known ✓ | P51451 | 10/20 | 1.00 |
| ▸ | AURKA known ✓ | O14965 | 10/20 | 1.00 |
| ▸ | FYN known ✓ | P06241 | 10/20 | 1.00 |
| ▸ | LYN known ✓ | P07948 | 9/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 9/20 | 1.00 |
| ▸ | LCK known ✓ | P06239 | 9/20 | 1.00 |
| ▸ | SRC known ✓ | P12931 | 8/20 | 1.00 |
| ▸ | FRK known ✓ | P42685 | 7/20 | 1.00 |
| ▸ | SRMS known ✓ | Q9H3Y6 | 5/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 5/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 4/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 3/20 | 1.00 |
| ▸ | AURKC known ✓ | Q9UQB9 | 1/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 11/20 | 1.00 |
| ▸ | CSF1R | P07333 | 10/20 | 1.00 |
| ▸ | STK3 | Q13188 | 10/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 10/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ilorasertib SCHEMBL29496449 | 1.00 | KDR (1.00) | KDRAURKBFGFR1CSF1RBLK | |
| Ilorasertib SCHEMBL29373142 | 1.00 | KDR (1.00) | KDRAURKBFGFR1CSF1RBLK | |
| Ilorasertib SCHEMBL11898929 | 0.99 | KDR (0.98) | KDRAURKBFGFR1CSF1RBLK | |
| Ilorasertib SCHEMBL30406133 | 0.99 | KDR (0.98) | KDRAURKBFGFR1CSF1RBLK | |
| Ilorasertib SCHEMBL11899788 | 0.97 | KDR (0.94) | KDRAURKBFGFR1CSF1RBLK | |
| Ilorasertib SCHEMBL11900182 | 0.97 | KDR (0.94) | KDRAURKBFGFR1CSF1RBLK | |
| Ilorasertib SCHEMBL11901361 | 0.97 | KDR (0.94) | KDRAURKBFGFR1CSF1RBLK | |
| Ilorasertib SCHEMBL27917339 | 0.97 | KDR (0.94) | KDRAURKBFGFR1CSF1RBLK | |
| Ilorasertib SCHEMBL11899442 | 0.96 | KDR (0.93) | KDRAURKBFGFR1CSF1RBLK | |
| Ilorasertib SCHEMBL11899597 | 0.96 | KDR (0.91) | KDRAURKBFGFR1CSF1RBLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210213037-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-07-15 | — | — | US | claimed |
| EP-3752161-A1 | METHODS FOR TREATING FIBROSIS | Children's Hospital Medical Center (US) | 2020-12-23 | — | — | EP | claimed |
| WO-2019161000-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-08-22 | — | — | WO | claimed |
| US-20170197980-A1 | N-(4-PHENYL)-N'-(3-FLUOROPHENYL)UREA DOCUSATE | ABBVIE INC (US) | 2017-07-13 | — | — | US | claimed |
| US-20160153052-A1 | MARKER TO PREDICT AND MONITOR RESPONSE TO AURORA KINASE B INHIBITOR THERAPY | ABBVIE INC. (US) | 2016-06-02 | — | — | US | claimed |
| WO-2015200635-A1 | N-(4-{4-AMINO-7-[1-(2-HYDROXYETHYL)-1H-PYRAZOL-4-yl]THIENO[3,2-c]PYRIDIN-3-YL}PHENYL)-N'-(3-FLUOROPHENYL)UREA DOCUSATE | ABBVIE INC. (US) | 2015-12-30 | — | — | WO | claimed |
| EP-2580221-B1 | CRYSTALLINE FORMS OF KINASE INHIBITORS | ABBVIE BAHAMAS LTD (BS) | 2015-10-21 | — | — | EP | claimed |
| US-20150126545-A1 | COMPOSITIONS CONTAINING KINASE INHIBITORS | ABBVIE INC. (US) | 2015-05-07 | — | — | US | claimed |
| EP-2580219-B1 | CRYSTALLINE FORMS OF KINASE INHIBITORS | ABBVIE BAHAMAS LTD (BS) | 2015-02-25 | — | — | EP | claimed |
| EP-2580220-B1 | CRYSTALLINE FORMS OF KINASE INHIBITORS | ABBVIE BAHAMAS LTD (BS) | 2015-02-11 | — | — | EP | claimed |
| US-8357804-B2 | Crystal forms of kinase inhibitors | ABBVIE INC. (US) | 2013-01-22 | — | — | US | claimed |
| US-20120309783-A1 | KINASE INHIBITORS WITH IMPROVED CYP SAFETY PROFILE | ABBOTT LABORATORIES (US) | 2012-12-06 | — | — | US | claimed |
| US-20120203002-A1 | Crystalline Forms of Kinase Inhibitors | ABBOTT LABORATORIES (US) | 2012-08-09 | — | — | US | claimed |
| US-20120202844-A1 | Crystal Forms of Kinase Inhibitors | ABBOTT LABORATORIES (US) | 2012-08-09 | — | — | US | claimed |
| US-20120149726-A1 | Crystal Forms of Kinase Inhibitors | ABBOTT LABORATORIES (US) | 2012-06-14 | — | — | US | claimed |
| WO-2011156464-A1 | CRYSTALLINE FORMS OF KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2011-12-15 | — | — | WO | claimed |
| WO-2011156473-A1 | CRYSTALLINE FORMS OF KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2011-12-15 | — | — | WO | claimed |
| US-20110306632-A1 | Solid Dispersions Containing Kinase Inhibitors | ABBOTT LABORATORIES (US) | 2011-12-15 | — | — | US | claimed |
| WO-2011156461-A1 | CRYSTALLINE FORMS OF KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2011-12-15 | — | — | WO | claimed |
| US-20100144783-A1 | KINASE INHIBITORS WITH IMPROVED CYP SAFETY PROFILE | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144783-A1 | KINASE INHIBITORS WITH IMPROVED CYP SAFETY PROFILE | CYP3A43, CYP3A4, CYP1A2 | KDR 28/4885AURKB 14/4885BLK 73/4885 |
| US-20120309783-A1 | KINASE INHIBITORS WITH IMPROVED CYP SAFETY PROFILE | CYP3A43, CYP3A4, CYP1A2 | KDR 28/4885AURKB 14/4885BLK 73/4885 |
| US-20170197980-A1 | N-(4-PHENYL)-N'-(3-FLUOROPHENYL)UREA DOCUSATE | UMPS, UPP1, SLC14A1 | KDR 2509/4885AURKB 2432/4885BLK 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.